AULTMAN HOSPITAL
- Type
- Teaching hospital
- Where
- Canton, OH
- Medicare CCN
- 360084
- Received
- $1,128,020 in 141 records, 2019 ($75,138 general, $1,052,882 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: Aultman Hospital Fuzzy (name and state)
- Federal award recipient: AULTMAN HOSPITAL Fuzzy (name and state)
- Federal award recipient: AULTMAN HOSPITAL, THE Fuzzy (name and state)
- Lobbying client: AULTMAN HOSPITAL Fuzzy (name and state)
- Lobbying client: AULTMAN HOSPITAL Fuzzy (name and state)
- Trademark owner: Aultman Hospital Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 52 | $75,138 |
| 2019 | Research payment | 89 | $1,052,882 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 89 | $1,052,882 |
| Space rental or facility fees (teaching hospital only) | 24 | $27,862 |
| Education | 4 | $24,276 |
| Grant | 5 | $15,227 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 13 | $5,615 |
| Charitable Contribution | 2 | $1,750 |
| Gift | 4 | $407 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $802 | Research payment | In-kind items and services | Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small Cell Lung Cancer NSCLC NEPTUNE | 2019 | |
| 2019-12-31 | Masimo Corporation | $82 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2019 | |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $82 | Research payment | In-kind items and services | A Phase III Randomized Multi Center OpenLabel Comparative Global Study to Determine the Efficacy of Durvalumab or Durval | 2019 | |
| 2019-12-25 | Amgen Inc. | $3,030 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | FOURIER OLE (Ph 4) | 2019 |
| 2019-12-19 | Sterilmed, Inc. | $39 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-12-16 | Boston Scientific Corporation | $1,791 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ASAP TOO | 2019 |
| 2019-12-16 | Boston Scientific Corporation | $1,756 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ASAP TOO | 2019 |
| 2019-12-16 | Boston Scientific Corporation | $400 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | IMPERIAL | 2019 |
| 2019-12-11 | Amgen Inc. | $1,255 | Research payment | Cash or cash equivalent | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC | 2019 |
| 2019-12-05 | Abbott Laboratories | $1,200 | Research payment | Cash or cash equivalent | ABSORB Device, Vascular | A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects | 2019 |
| 2019-12-03 | Kowa Research Institute, Inc. | $4,290 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2019 |
| 2019-11-28 | PFIZER INC. | $221 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-22 | Medline Industries LP | $500 | Charitable Contribution | Cash or cash equivalent | 2019 | ||
| 2019-11-22 | Kowa Research Institute, Inc. | $448 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2019 |
| 2019-11-21 | TESARO, Inc. | $40,143 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-11-19 | Sterilmed, Inc. | $39 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-11-18 | Boston Scientific Corporation | $125 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product | PREEMPT HF | 2019 |
| 2019-11-08 | American Regent | $520 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2019 |
| 2019-11-04 | Boston Scientific Corporation | $1,321 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | IMPERIAL | 2019 |
| 2019-11-04 | Boston Scientific Corporation | $845 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ASAP TOO | 2019 |
| 2019-10-30 | TESARO, Inc. | $53,524 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-10-25 | Kowa Research Institute, Inc. | $3,933 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2019 |
| 2019-10-23 | Sterilmed, Inc. | $36 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-10-21 | Boston Scientific Corporation | $16,439 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product | PREEMPT HF | 2019 |
| 2019-10-09 | American Regent | $6,180 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2019 |
| 2019-10-07 | EMD Serono, Inc. | $1,250 | Charitable Contribution | Cash or cash equivalent | Bavencio Biological, Oncology | 2019 | |
| 2019-10-01 | Kowa Research Institute, Inc. | $1,760 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2019 |
| 2019-09-25 | TESARO, Inc. | $40,143 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-09-19 | Pharmacyclics LLC, an AbbVie Company | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Imbruvica Drug, Oncology | 2019 | |
| 2019-09-19 | Medical Device Business Services, Inc. | $1,100 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-09-18 | Janssen Biotech, Inc. | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Erleada Drug, Oncology | 2019 | |
| 2019-09-16 | Boston Scientific Corporation | $1,512 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ASAP TOO | 2019 |
| 2019-09-16 | Boston Scientific Corporation | $440 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | IMPERIAL | 2019 |
| 2019-09-14 | TESARO, Inc. | $1,262 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | 2019 | |
| 2019-09-14 | Novartis Pharmaceuticals Corporation | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-09-14 | Novartis Pharmaceuticals Corporation | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VOTRIENT Drug, ONCOLOGY | 2019 | |
| 2019-09-13 | Boston Scientific Corporation | $586 | Research payment | Cash or cash equivalent | ACUITY Device, TACHY | NAVIGATE X4 STUDY | 2019 |
| 2019-09-13 | Medical Graphics Corporation | $226 | Gift (2 payments) | In-kind items and services | 2019 | ||
| 2019-09-12 | TESARO, Inc. | $26,762 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-09-05 | Abbott Laboratories | $650 | Research payment | Cash or cash equivalent | ABSORB Device, Vascular | A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects | 2019 |
| 2019-09-04 | Sterilmed, Inc. | $20 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-08-30 | Boston Scientific Corporation | $7,727 | Grant | In-kind items and services | ILab Device, Imaging | 2019 | |
| 2019-08-29 | PFIZER INC. | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BOSULIF Drug, METABOLIC DISEASE;ONCOLOGY | 2019 | |
| 2019-08-28 | TESARO, Inc. | $40,143 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-08-28 | PFIZER INC. | $616 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-19 | TESARO, Inc. | $40,143 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-08-16 | E.R. Squibb & Sons, L.L.C. | $33 | Research payment | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K A | 2019 |
| 2019-08-14 | PFIZER INC. | $663 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-13 | AstraZeneca Pharmaceuticals LP | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2019 | |
| 2019-08-07 | Amgen Inc. | $1,382 | Research payment | In-kind items and services | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC | 2019 |
| 2019-08-05 | Boston Scientific Corporation | $3,582 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ASAP TOO | 2019 |
| 2019-08-05 | Boston Scientific Corporation | $2,200 | Research payment | Cash or cash equivalent | INGEVITY Device, BRADY | INGEVITY | 2019 |
| 2019-08-05 | Boston Scientific Corporation | $200 | Research payment | Cash or cash equivalent | INGEVITY Device, BRADY | INGEVITY | 2019 |
| 2019-08-01 | Sterilmed, Inc. | $14 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-07-29 | Lilly USA, LLC | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-07-29 | Merck Sharp & Dohme LLC | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-07-19 | TAIHO ONCOLOGY, INC. | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Lonsurf Drug, Oncology | 2019 | |
| 2019-07-17 | TESARO, Inc. | $40,143 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-07-16 | TESARO, Inc. | $40,995 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-07-11 | JAZZ PHARMACEUTICALS INC. | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-07-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-07-08 | American Regent | $7,659 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2019 |
| 2019-07-05 | Bayer Healthcare Pharmaceuticals Inc. | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Xofigo Drug, Oncology | 2019 | |
| 2019-07-02 | PFIZER INC. | $1,623 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-06-29 | Daiichi Sankyo Inc. | $6,105 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | DS8201AU201 | 2019 |
| 2019-06-27 | GE HEALTHCARE | $4,533 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-06-26 | PFIZER INC. | $616 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-06-26 | Sterilmed, Inc. | $83 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-06-24 | SANOFI US SERVICES INC. | $5,000 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotaglifloz | 2019 |
| 2019-06-20 | Agios Pharmaceuticals, Inc. | $1,250 | Education | Cash or cash equivalent | IDHIFA Drug, ONCOLOGY | 2019 | |
| 2019-06-19 | TESARO, Inc. | $40,143 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-06-18 | Astellas Pharma US Inc | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | 2019 | |
| 2019-06-18 | Merck Sharp & Dohme LLC | $96 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
| 2019-06-14 | Boston Scientific Corporation | $1,316 | Research payment | Cash or cash equivalent | ACUITY Device, TACHY | NAVIGATE X4 STUDY | 2019 |
| 2019-06-07 | Abbott Laboratories | $2,750 | Research payment | Cash or cash equivalent | ABSORB Device, Vascular | A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects | 2019 |
| 2019-06-07 | Abbott Laboratories | $950 | Research payment | Cash or cash equivalent | ABSORB Device, Vascular | A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects | 2019 |
| 2019-06-06 | AstraZeneca Pharmaceuticals LP | $2,700 | Research payment | Cash or cash equivalent | A Phase III Randomized Multi Center OpenLabel Comparative Global Study to Determine the Efficacy of Durvalumab or Durval | 2019 | |
| 2019-06-03 | Boston Scientific Corporation | $2,000 | Research payment | Cash or cash equivalent | ACUITY Device, TACHY | NAVIGATE X4 STUDY | 2019 |
| 2019-05-31 | Amgen Inc. | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Blincyto Biological, Oncology | 2019 | |
| 2019-05-29 | PFIZER INC. | $663 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-05-29 | Sterilmed, Inc. | $61 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-05-28 | Genentech USA, Inc. | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Avastin Biological, BioOncology | 2019 | |
| 2019-05-25 | Amgen Inc. | $12,395 | Research payment | Cash or cash equivalent | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC | 2019 |
| 2019-05-23 | Ipsen Biopharmaceuticals, Inc | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SOMATULINE DEPOT Drug, Oncology/Endocrinology | 2019 | |
| 2019-05-22 | Amgen Inc. | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Neulasta Biological, Oncology | 2019 | |
| 2019-05-20 | TESARO, Inc. | $13,381 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-05-20 | Boston Scientific Corporation | $4,500 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product | PREEMPT HF | 2019 |
| 2019-05-20 | ZOLL Medical Corporation | $200 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, DEFIBRILLATOR | 2019 | |
| 2019-05-17 | Medical Device Business Services, Inc. | $4,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-05-15 | PFIZER INC. | $221 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-05-13 | E.R. Squibb & Sons, L.L.C. | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | OPDIVO Biological, Oncology | 2019 | |
| 2019-05-06 | Abbott Laboratories | $660 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-05-03 | Amgen Inc. | $114,972 | Research payment | In-kind items and services | Repatha Biological, Cardiology | FOURIER OLE (Ph 4) | 2019 |
| 2019-04-29 | ZOLL Medical Corporation | $2,700 | Education | Cash or cash equivalent | Device, DEFIBRILLATOR | 2019 | |
| 2019-04-25 | Sterilmed, Inc. | $10 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-04-23 | Biosense Webster, Inc. | $20,244 | Education | In-kind items and services | Carto 3 System Device, Cardiology | 2019 | |
| 2019-04-22 | Boston Scientific Corporation | $5,000 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ASAP TOO | 2019 |
| 2019-04-22 | Boston Scientific Corporation | $540 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | IMPERIAL | 2019 |
| 2019-04-22 | Boston Scientific Corporation | $400 | Research payment | Cash or cash equivalent | INGEVITY Device, BRADY | INGEVITY | 2019 |
| 2019-04-19 | Janssen Pharmaceuticals, Inc | $200 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XARELTO Drug, Cardiovascular & Metabolism | 2019 | |
| 2019-04-17 | AstraZeneca Pharmaceuticals LP | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | IMFINZI Drug, Cardiovascular and Metabolism | 2019 | |
| 2019-04-10 | PFIZER INC. | $10,640 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-04-10 | American Regent | $2,777 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2019 |
| 2019-04-10 | PFIZER INC. | $2,600 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-04-10 | PFIZER INC. | $1,400 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-04-10 | PFIZER INC. | $1,359 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-04-10 | PFIZER INC. | $826 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-04-10 | PFIZER INC. | $616 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-04-04 | AstraZeneca Pharmaceuticals LP | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2019 | |
| 2019-04-02 | Medical Device Business Services, Inc. | $1,400 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-04-02 | CSL Behring | $200 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-03-28 | Amgen Inc. | $750 | Research payment | In-kind items and services | Repatha Biological, Cardiology | FOURIER OLE (Ph 4) | 2019 |
| 2019-03-27 | Amgen Inc. | $1,212 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | FOURIER OLE (Ph 4) | 2019 |
| 2019-03-26 | Sterilmed, Inc. | $79 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-03-23 | Olympus America Inc. | $119 | Gift | In-kind items and services | Olympus Vent Tubes Device, ENT Products | 2019 | |
| 2019-03-23 | Olympus America Inc. | $46 | Gift | In-kind items and services | Olympus Vent Tubes Device, ENT Products | 2019 | |
| 2019-03-23 | Olympus America Inc. | $14 | Gift | In-kind items and services | Device, Surgical Endoscopy Products | 2019 | |
| 2019-03-20 | PFIZER INC. | $628 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-03-18 | Boston Scientific Corporation | $880 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | IMPERIAL | 2019 |
| 2019-03-18 | Boston Scientific Corporation | $715 | Research payment | Cash or cash equivalent | ACUITY Device, TACHY | NAVIGATE X4 STUDY | 2019 |
| 2019-03-15 | Sterilmed, Inc. | $11 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-03-13 | Abbott Laboratories | $2,800 | Research payment | Cash or cash equivalent | Absorb Device, Vascular | A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects | 2019 |
| 2019-03-08 | Medical Device Business Services, Inc. | $1,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-03-05 | TESARO, Inc. | $23,174 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-03-04 | Novartis Pharmaceuticals Corporation | $7,478 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | A MULTICENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LCZ6 | 2019 |
| 2019-02-26 | TESARO, Inc. | $6,000 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-02-21 | Novartis Pharmaceuticals Corporation | $1,520 | Research payment | Cash or cash equivalent | KISQALI Drug, ONCOLOGY | AN OPEN LABEL MULTICENTER PHASE IIIB STUDY OF RIBOCICLIB LEE011 IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTM | 2019 |
| 2019-02-20 | PFIZER INC. | $663 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-02-13 | PFIZER INC. | $4,148 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-02-11 | Amgen Inc. | $50,139 | Research payment | In-kind items and services | Repatha Biological, Cardiology | FOURIER OLE (Ph 4) | 2019 |
| 2019-02-04 | Novartis Pharmaceuticals Corporation | $16,930 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | A 24 WEEK RANDOMIZED DOUBLE BLIND MULTI CENTER PARALLEL GROUP ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFECT OF LCZ696 O | 2019 |
| 2019-01-29 | Amgen Inc. | $26,091 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | FOURIER OLE (Ph 4) | 2019 |
| 2019-01-28 | Novartis Pharmaceuticals Corporation | $171,644 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | PROSPECTIVE COMPARISON OF ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR ARNI VERSUS ACE INHIBITOR TRIAL TO DETERMINE IMPACT | 2019 |
| 2019-01-24 | AstraZeneca Pharmaceuticals LP | $14,710 | Research payment | Cash or cash equivalent | Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small Cell Lung Cancer NSCLC NEPTUNE | 2019 | |
| 2019-01-24 | Sterilmed, Inc. | $25 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-01-22 | Boston Scientific Corporation | $600 | Research payment | Cash or cash equivalent | ACUITY Device, TACHY | NAVIGATE X4 STUDY | 2019 |
| 2019-01-21 | American Regent | $8,608 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2019 |
| 2019-01-15 | AstraZeneca Pharmaceuticals LP | $17,941 | Research payment | Cash or cash equivalent | BRILINTA Drug, Cardiovascular and Metabolism | A Multinational Randomised Double Blind Placebo Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice dai | 2019 |
| 2019-01-08 | Eli Lilly and Company | $71,683 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD | 2019 | |
| 2019-01-07 | Amgen Inc. | $515 | Research payment | In-kind items and services | Repatha Biological, Cardiology | FOURIER OLE (Ph 4) | 2019 |
| 2019-01-03 | Amgen Inc. | $525 | Research payment | In-kind items and services | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Canton, OH, county Stark County, OH, state Ohio; placed by its city name.
| Measure | Place (city or town) Canton, OH | County Stark County, OH | State Ohio |
|---|---|---|---|
| Population B01003 | 69,755 | 373,713 | 11,810,293 |
| Population, 2020 census P1 | 70,872 | 374,853 | 11,799,448 |
| Median age B01002 | 35.2 | 41.8 | 39.7 |
| Under 18 B01001 | 25.4% | 21.5% | 22.0% |
| 65 and over B01001 | 15.7% | 20.5% | 18.3% |
| Households B11001 | 29,302 | 155,955 | 4,863,191 |
| Foreign born B05002 | 2.5% | 2.2% | 5.2% |
| Median household income B19013 | $43,188 | $67,934 | $71,389 |
| Median family income B19113 | $53,992 | $86,156 | $92,749 |
| Per capita income B19301 | $24,690 | $36,762 | $40,552 |
| Poverty rate B17001 | 27.4% | 12.5% | 13.3% |
| Unemployment rate B23025 | 7.8% | 3.9% | 4.8% |
| Civilian labor force B23025 | 32,390 | 186,713 | 5,994,779 |
| Mean commute (minutes) B08013 | 19.1 | 21.7 | 23.4 |
| Bachelor's degree or higher B15003 | 16.4% | 25.9% | 31.5% |
| Housing units B25001 | 33,836 | 167,949 | 5,292,391 |
| Owner-occupied B25003 | 48.7% | 69.2% | 67.2% |
| Renters B25003 | 51.3% | 30.8% | 32.8% |
| Median home value B25077 | $97,800 | $186,400 | $214,800 |
| Median gross rent B25064 | $850 | $909 | $1,034 |
| White, not Hispanic B03002 | 59.0% | 83.8% | 75.8% |
| Black B03002 | 23.4% | 7.1% | 12.0% |
| Hispanic or Latino B03002 | 6.7% | 3.0% | 4.8% |
| Asian B03002 | 0.6% | 0.9% | 2.5% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Canton, OH.
Comments